Form 4: Iradimed Corp Insider Sells Shares Under 10b5-1 Plan

Roger E. Susi, CEO and Director of Iradimed Corp, reported the sale of common stock totaling over 7,000 shares across multiple transactions executed between April 27-28, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, who holds the positions of CEO, President, Chairman, Director, and is a 10% owner of Iradimed Corporation, has reported a series of stock sales.
• These transactions occurred on April 27 and April 28, 2026.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• A total of 7,000 shares were sold across eight separate transactions, with weighted average sale prices ranging from $84.13 to $89.70 per share.
• Following these transactions, Susi's beneficial ownership of Iradimed Corp common stock is detailed, with holdings directly and indirectly through various trusts and his revocable trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the insider selling, but the use of a Rule 10b5-1 plan significantly mitigates negative sentiment by indicating a pre-planned and compliant transaction.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to selling shares, which can mitigate concerns about insider trading.
• Roger E. Susi retains significant beneficial ownership of Iradimed Corp stock, both directly and indirectly, suggesting continued commitment to the company.

Negatives

• The reporting person, a key executive and director, has sold a notable number of shares, which could be interpreted negatively by the market.
• The total value of shares sold across the reported transactions is substantial, although specific aggregate figures are not provided in the filing.

Risks

• The sale of a significant number of shares by a key executive could signal a lack of confidence in future stock performance, although the 10b5-1 plan mitigates this interpretation.
• Market perception of insider selling, even under a 10b5-1 plan, can sometimes lead to downward pressure on the stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for multiple transactions.
• The reporting person disclaims beneficial ownership of certain shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a CEO of a publicly traded company like Iradimed Corp (IRMD) is a common practice to diversify holdings or manage personal finances in a way that complies with securities regulations.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, potentially impacting stock price, though the 10b5-1 plan provides a degree of reassurance.
• Employees: May be concerned about executive confidence in the company's future, depending on the scale of the sales.
• Management: The transactions are executed by a key executive, highlighting the importance of transparent and compliant insider trading practices.

Next Steps

• Continued monitoring of insider transactions for any further sales or purchases.
• Analysis of Iradimed Corp's overall financial performance and strategic initiatives to contextualize insider trading activity.

Key Dates

Recommendation

The filing reports routine stock sales by a key executive under a pre-established 10b5-1 plan. While insider selling can be a negative indicator, the structured nature of the plan suggests it's not necessarily a reflection of a lack of confidence in the company's future. Without additional financial performance data or strategic updates in this specific filing, a 'hold' recommendation is appropriate, pending further information.

Keywords

Iradimed Corp, IRMD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Roger E. Susi, SEC Filing, Executive Compensation